CO2022013715A2 - Vacuna inactivada contra el virus sars-cov-2 - Google Patents

Vacuna inactivada contra el virus sars-cov-2

Info

Publication number
CO2022013715A2
CO2022013715A2 CONC2022/0013715A CO2022013715A CO2022013715A2 CO 2022013715 A2 CO2022013715 A2 CO 2022013715A2 CO 2022013715 A CO2022013715 A CO 2022013715A CO 2022013715 A2 CO2022013715 A2 CO 2022013715A2
Authority
CO
Colombia
Prior art keywords
cov
virus
vaccine against
inactivated vaccine
against sars
Prior art date
Application number
CONC2022/0013715A
Other languages
English (en)
Inventor
Andreas Meinke
Jürgen Heindl-Wruss
Robert Schlegl
Michael Möhlen
Original Assignee
Valneva Austria Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2021/020313 external-priority patent/WO2021178318A1/en
Priority claimed from PCT/EP2021/058974 external-priority patent/WO2021204825A2/en
Application filed by Valneva Austria Gmbh filed Critical Valneva Austria Gmbh
Publication of CO2022013715A2 publication Critical patent/CO2022013715A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20061—Methods of inactivation or attenuation
    • C12N2770/20063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Aquí se describen vacunas contra el SARS-CoV-2 y composiciones y métodos para producir y administrar dichas vacunas a sujetos que las necesitan
CONC2022/0013715A 2020-04-06 2022-09-23 Vacuna inactivada contra el virus sars-cov-2 CO2022013715A2 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20168324 2020-04-06
EP20202118 2020-10-15
EP20211853 2020-12-04
EP21154647 2021-02-01
PCT/US2021/020313 WO2021178318A1 (en) 2020-03-01 2021-03-01 Coronavirus vaccines comprising a tlr9 agonist
EP21160913 2021-03-05
PCT/EP2021/058974 WO2021204825A2 (en) 2020-04-06 2021-04-06 INACTIVATED SARS-CoV-2 VIRUS VACCINE

Publications (1)

Publication Number Publication Date
CO2022013715A2 true CO2022013715A2 (es) 2022-12-30

Family

ID=79566178

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0013715A CO2022013715A2 (es) 2020-04-06 2022-09-23 Vacuna inactivada contra el virus sars-cov-2

Country Status (14)

Country Link
US (1) US20240293531A1 (es)
EP (1) EP3955959A2 (es)
JP (1) JP2023520521A (es)
KR (1) KR20220164500A (es)
CN (1) CN115768469A (es)
AU (1) AU2021253605A1 (es)
BR (1) BR112022020100A2 (es)
CA (1) CA3168784A1 (es)
CL (1) CL2022002365A1 (es)
CO (1) CO2022013715A2 (es)
EC (1) ECSP22072590A (es)
IL (1) IL296072A (es)
MX (1) MX2022012447A (es)
ZA (1) ZA202209826B (es)

Also Published As

Publication number Publication date
CA3168784A1 (en) 2021-10-14
CL2022002365A1 (es) 2023-02-03
IL296072A (en) 2022-11-01
MX2022012447A (es) 2022-10-27
US20240293531A1 (en) 2024-09-05
ZA202209826B (en) 2023-05-31
CN115768469A (zh) 2023-03-07
EP3955959A2 (en) 2022-02-23
ECSP22072590A (es) 2022-10-31
KR20220164500A (ko) 2022-12-13
AU2021253605A1 (en) 2022-10-06
JP2023520521A (ja) 2023-05-17
BR112022020100A2 (pt) 2022-11-29

Similar Documents

Publication Publication Date Title
ECSP22072586A (es) VACUNA CONTRA EL VIRUS SARS-CoV-2 CON ADYUVANTE CpG
UY39159A (es) VACUNA INACTIVADA CONTRA EL VIRUS DEL SARS-CoV-2
MX2018007627A (es) Vacuna contra el virus del zika.
BR112018016755A2 (pt) vacina contra o vírus da zica
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
PE20151588A1 (es) Vacuna contra el virus del dengue
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
CO2021003931A2 (es) Dosis unitaria de vacuna contra el dengue y administración de esta
BR112013017171A2 (pt) vacina de combinação imunogênica estável, processo de preparação de vacina de combinação estável, método de uso de moléculas antigênicas e método de administração a indivíduos humanos
MX2020004633A (es) Metodo para inactivar el virus de zika y metodos relacionados.
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
CO2022012272A2 (es) Vacunas contra el coronavirus y métodos de uso
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
BR112022020298A2 (pt) Vacinas, adjuvantes e métodos para gerar uma resposta imune
MX2022010781A (es) Vacuna contra el virus sars-cov-2 con adyuvante cpg.
CO2021009379A2 (es) Formulaciones y métodos de la vacuna contra el norovirus
BR112018008697A2 (pt) método e kit para vacinação contra um auto-antígeno, uso de um kit, e, vacina para uso em vacinação.
CO2022013715A2 (es) Vacuna inactivada contra el virus sars-cov-2
CL2009000287A1 (es) Composicion que comprende un alfavirus salmonideo (sav) inactivado y al menos un componente seleccionado de una bacteria muerta/inactivada, otro virus inactivado, un hongo, un parasito y un material antigenico derivado de la bacteria, virus, hongo o parasito anterior; metodo para elaborar la composicion y uso del sav.
UY38933A (es) Vacuna de partículas tipo virus del chicunguña y métodos para su uso
BRPI0811459A8 (pt) Preparação virossômica, uso de uma preparação virossômica, kit, e, métodos para vacinar um ser humano contra infecções de influenza, e para vacinar indivíduos mamíferos contra infecções da influenza
CL2015003445A1 (es) Uso del virus de la necrosis nerviosa del jurel (sjnnv) para la protección de peces contra infección por el virus de la necrosis nerviosa del mero de manchas rojas (rgnnv); vacuna que comprende sjnnv; y método para proteger peces contra infección por rgnnv.
BR112022008711A2 (pt) Métodos para produzir uma vacina viral e reduzir o tamanho da partícula viral
AR121151A1 (es) Formulaciones para vacuna contra coronavirus